Stemline Therapeutics (STML) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
Go back to Stemline Therapeutics (STML) Misses Q4 EPS by 2c
March 13, 2015 6:04 PM EDT
NEW YORK, March 13, 2015 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical stage biopharmaceutical company developing novel drugs targeting cancer stem cells (CSCs) and tumor bulk, today reported financial results for the quarter ended December 31, 2014.
Ivan Bergstein, M.D., Stemline's Chief Executive Officer, commented, "The last few months have been extremely productive for Stemline, highlighted by continued patient enrollment in our SL-401 and SL-701 trials, the in-licensing of SL-801, a novel, reversible XPO1 inhibitor, and the successful completion of a $68 million public offering." Dr. Bergstein continued, "We look forward to an... More
March 13, 2015 6:04 PM EDT
NEW YORK, March 13, 2015 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical stage biopharmaceutical company developing novel drugs targeting cancer stem cells (CSCs) and tumor bulk, today reported financial results for the quarter ended December 31, 2014.
Ivan Bergstein, M.D., Stemline's Chief Executive Officer, commented, "The last few months have been extremely productive for Stemline, highlighted by continued patient enrollment in our SL-401 and SL-701 trials, the in-licensing of SL-801, a novel, reversible XPO1 inhibitor, and the successful completion of a $68 million public offering." Dr. Bergstein continued, "We look forward to an... More
